13
Participants
Start Date
November 29, 2019
Primary Completion Date
May 31, 2023
Study Completion Date
March 30, 2024
Nivolumab
"The dose of Nivolumab will be 3 mg/kg which is the adult recommended dose and is the recommended dose in children in the phase 2 portion of COG ADVL1412.~If 3 mg/kg is not tolerated in combination with 5-azacytidine, the dose will be stepped down to 1 mg/kg."
5-azacytidine
75mg/m2 subcutaneously will be given daily for 7 days on days 1 to 7.
Columbia University Medical Center, New York
Johns Hopkins University, Baltimore
Levine Cancer Institute, Charlotte
Children's Healthcare of Atlanta, Atlanta
St. Jude Children's Research Hospital, Memphis
Cincinnati Children's Hospital Medical Center, Cincinnati
Children's Health, Dallas
Cook Children's Medical Center, Fort Worth
Texas Children's Hospital/Baylor College of Medicine, Houston
Primary Children's Hospital, Salt Lake City
Children's Hospital of Los Angeles, Los Angeles
Seattle Children's Hospital, Seattle
Collaborators (1)
Bristol-Myers Squibb
INDUSTRY
Therapeutic Advances in Childhood Leukemia Consortium
OTHER